Market Closed -
Nasdaq
16:00:00 2024-05-17 EDT
5-day change
1st Jan Change
138
USD
+2.26%
+6.15%
+74.81%
Presenter SpeechK. Gong (Analysts)Okay. Good morning, everyone, and welcome to Wednesday of th...
This article is reserved for subscribers
Signed up already?
Log In Not subscribed yet?
Subscribe
Transmedics Group Insider Sold Shares Worth $3,902,100, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $759,479, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $930,278, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $1,920,000, According to a Recent SEC Filing
05-08
MT
Transmedics Group Insider Sold Shares Worth $7,986,219, According to a Recent SEC Filing
05-03
MT
Transmedics Group Insider Sold Shares Worth $1,600,633, According to a Recent SEC Filing
05-03
MT
TransMedics Group Shares Rise as Q1 Swings to Net Income, Revenue Rises; Increases 2024 Revenue Outlook
05-01
MT
Oppenheimer Adjusts TransMedics Group Price Target to $125 From $105, Maintains Outperform Rating
05-01
MT
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q1 Revenue $96.9M, vs. Street Est of $83.8M
04-30
MT
TransMedics Group, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
04-30
CI
Transcript : TransMedics Group, Inc., Q1 2024 Earnings Call, Apr 30, 2024
04-30
TransMedics Group, Inc. Raises Revenue Guidance for the Full Year 2024
04-30
CI
Transmedics Group Insider Sold Shares Worth $380,480, According to a Recent SEC Filing
04-18
MT
Transmedics Group Insider Sold Shares Worth $802,084, According to a Recent SEC Filing
04-05
MT
Transmedics Group Insider Sold Shares Worth $1,110,150, According to a Recent SEC Filing
04-02
MT
Piper Sandler Initiates TransMedics Group With Overweight Rating, $95 Price Target
03-28
MT
Oppenheimer Adjusts TransMedics Group Price Target to $105 From $92, Maintains Outperform Rating
02-27
MT
Top Premarket Gainers
02-27
MT
Transcript : TransMedics Group, Inc., Q4 2023 Earnings Call, Feb 26, 2024
02-26
TransMedics Group Swings to Net Income in Q4, Revenue Increases; Sets 2024 Revenue Outlook-- Shares Rise
02-26
MT
TransMedics Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
02-26
CI
TransMedics Group, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
02-26
CI
Earnings Flash (TMDX) TRANSMEDICS GROUP Posts Q4 Revenue $81.2M, vs. Street Est of $68.5M
02-26
MT
Transmedics Group, Inc. Provides Revenue Guidance for the Full-Year 2024
02-26
CI
Transmedics Group Insider Sold Shares Worth $279,720, According to a Recent SEC Filing
02-21
MT
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ retrieval, OCS organ management and logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation, ground transportation and other coordination activity. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
More about the company
Average target price
120.5
USD
Spread / Average Target
-12.67%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1